The reiteration of the Buy rating and the significant increase in the price target by HC Wainwright & Co. analyst Joseph Pantginis indicates a positive outlook for Panbela Therapeutics. This news is likely to have a positive impact on the stock price in the short term as it reflects increased confidence in the company's prospects.